Table 2 Seroprotection pre-vaccination.
All patients | CD19 | BCMA | P-value1 | |
|---|---|---|---|---|
Diphtheria (n = 70) | ||||
Protected, n (%) | 49 (70%) | 41 (84%) | 8 (38%) | 0.003 |
Tetanus (n = 69) | ||||
Protected, n (%) | 61 (88%) | 47 (98%) | 14 (67%) | 0.006 |
Polio I (n = 64) | ||||
Protected, n (%) | 56 (88%) | 45 (98%) | 11 (61%) | 0.003 |
Polio 3 (n = 64) | ||||
Protected, n (%) | 58 (91%) | 46 (100%) | 12 (67%) | 0.002 |
Pertussis (68) | ||||
Protected, n (%) | 20 (29%) | 20 (43%) | 0 (0%) | 0.001 |
Pneumococcus (n = 66) | ||||
Protected, n (%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Haemophilus B (n = 63) | 16 (23%) | 14 (29%) | 2 (10%) | 0.071 |
Varicella (n = 64) | ||||
Protected, n (%) | 43 (67%) | 39 (85%) | 4 (22%) | <0.001 |
Hepatitis A (n = 64) | ||||
Protected, n (%) | 31 (48%) | 25 (56%) | 6 (32%) | >0.99 |
Hepatitis B (n = 63) | 19 (30%) | 15 (34%) | 4 (21%) | >0.99 |
Measles (n = 8) | ||||
Protected, n (%) | 2 (25%) | 2 (25%) | ND | |
Mumps (n = 8) | ||||
Protected, n (%) | 5 (62%) | 5 (62%) | ND | |
Rubella (n = 8) | ||||
Protected, n (%) | 3 (38%) | 3 (38%) | ND | |
